
Immunovant Inc (IMVT) Stock Forecast & Price Target
Immunovant Inc (IMVT) Analyst Ratings
Bulls say
Immunovant Inc. demonstrates a positive outlook due to the promising sustained reduction in TRAb levels during the off-treatment period, indicating the potential of FcRn blockers as disease-modifying therapies in autoimmune conditions like Graves' disease (GD). The impressive responder rate of 81% during the 6-month off-treatment phase, comparable to rates seen during active treatment, strengthens confidence in the durability of the therapeutic effect. Additionally, the effectiveness observed in patients unresponsive to conventional anti-thyroid drug therapy underlines the significant clinical value of Immunovant's innovative approach to treating autoimmune diseases.
Bears say
Immunovant Inc. faces a negative outlook due to the implications of persistently high TRAbs, which are linked to increased relapse rates in patients. The company's primary focus on developing IMVT-1402 as a treatment for autoimmune diseases may be compromised by the potential complications arising from TRAbs-mediated TSHR activation, which can lead to significant health risks such as inflammation and vision impairment. Additionally, the challenges associated with managing these adverse effects could hinder the company's developmental progress and market potential, thereby impacting its overall financial stability.
This aggregate rating is based on analysts' research of Immunovant Inc and is not a guaranteed prediction by Public.com or investment advice.
Immunovant Inc (IMVT) Analyst Forecast & Price Prediction
Start investing in Immunovant Inc (IMVT)
Order type
Buy in
Order amount
Est. shares
0 shares